US Edition
Published • loading... • Updated
New research highlights Entropy’s leading position in the psychedelic therapeutics market
Summary by Stockhead
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
New research highlights Entropy’s leading position in the psychedelic therapeutics market
Prenzler Group initiates coverage on clinical-stage, psilocin focused Entropy Neurodynamics The Sydney based firm says Entropy’s patented precision intravenous (IV) dosing of psilocin differentiates it from peers using oral psilocybin The company well-funded to deliver on near term catalysts, including a world-first binge eating disorder trial Special Report: Prenzler Group has initiated coverage of Entropy Neurodynamics, noting the medical p…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
